AVTE Company Profile and Key Details

Aerovate Therapeutics, Inc. generated EPS of -$1.70 over the past year. Five-year average earnings growth is -77.98%. Wall Street analysts project EPS growth of 34.03% annually over the next five years. The latest quarter delivered EPS of -$1.13. The next quarter is forecast at -$0.27. Next year's EPS is expected at $8.30. Aerovate Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2025, missed forecasts by 352.1%. The prior quarter beat by -70.0%. Over the last six quarters, Apple has recorded several small beats. These include 12.16% in May 13, 2024.

Short-term trend indicators are mixed aligned (SMA20 -0.8%, SMA50 -0.8%, SMA200 -0.8%). The stock remains hovering near 52-week lows, trading -6.29% below its high and over 7.2% above its low.

Aerovate Therapeutics, Inc. has 28.98 million shares outstanding. The public float is 341.84 thousand shares, elevated short interest at 1.15% of float. This equals 131.23 thousand shares. The short ratio is 26.71 days. Institutional investors hold 110.82% of the float. Insiders own 0.02%. RA CAPITAL MANAGEMENT, L.P. holds 7.89 million shares, GRAYZEL DAVID S. has 14.50 thousand shares and Gillies Hunter has 5.60 thousand shares.

The stock is currently within 5% of its 52-week low $2.63 and $884.98. With a market capitalization of about $77.68 million, Aerovate Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 7.99 thousand shares, trading with heavier-than-usual volume. Headquartered in Waltham, MA, Aerovate Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Timothy P. Noyes, the company employs approximately 4 people and listed since June 30, 2021. Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.

Aerovate Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.17. This means the shares are trading above this model’s fair value.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) shares are flat 1.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aerovate Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.63. Analyst sentiment is cautious, with the majority of ratings in In-Line territory and a mean price target of $25.82, suggesting -72.47% downside. Our AI forecast model points to short-term weakness (-97.0% over two weeks), a medium-term fall (-97.31% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Aerovate Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -97.0%, with price expected at $2.81 by May 12, 2025, within a range of $2.75 to $2.87 3-Month Outlook: Projected fall of -97.31%, reaching $2.52 by July 25, 2025, with a range of $1.38 to $2.87. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 28, 2026, within a range of $0.00 to $0.81.

Aerovate Therapeutics, Inc. trades at a P/E ratio of -1.63, slightly below the S&P 500 average, with a price-to-sales ratio of 693.57 and a price-to-book ratio of 0.59 suggesting the stock is closer to book value. The P/FCF stands at -1.07, also above market averages.